Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT02576639 | Dose-ranging Safety and Tolerability Study in Subjects ≥60 Years of Age | PHASE2 | COMPLETED | 124 | — | — | Aug 10, 2015 | Mar 11, 2016 | Aug 11, 2017 | 11 | United States, Belgium +3 |
Safety monitoring was conducted throughout the study.
| Arm | Type | Description |
|---|---|---|
| Placebo | PLACEBO_COMPARATOR | Matching placebo to CNP520 was taken once daily (qd) orally for 13 weeks. |
| CNP520 2 mg | EXPERIMENTAL | CNP520 2 mg was taken qd orally for 13 weeks. |
| CNP520 10 mg | EXPERIMENTAL | CNP520 10 mg was taken qd orally for 13 weeks. |
| CNP520 35 mg | EXPERIMENTAL | CNP520 35 mg was taken qd orally for 13 weeks. |
| CNP520 85 mg | EXPERIMENTAL | CNP520 85 mg was taken qd orally for 13 weeks. |
| Name | Type | Description |
|---|---|---|
| CNP520 | DRUG | - |
| Placebo | DRUG | Matching placebo to CNP520 was supplied in capsules. |
Key Inclusion Criteria: * Healthy status * Body weight: ≥45kg * BMI: 18-34 kg/m2 Key Exclusion Criteria: * History or presence of any clinically significant disease of any major system organ class. * Heavy smoker status * History /presence of clinically significant neurological or psychiatric dis...